Semaglutide Dosage Guide: Reconstitution, Escalation Protocol & Syringe Units

Semaglutide research dosage guide: standard escalation from 0.25 mg to 2.4 mg/week, STEP trial weight loss data, reconstitution math, and pre-filled syringe calculator.

TL;DR

• Semaglutide is a GLP-1 receptor agonist with 94% homology to native GLP-1, administered once weekly via subcutaneous injection
• The STEP-1 clinical trial demonstrated ~14.9% mean body weight reduction over 68 weeks at 2.4 mg/week
• Research escalation protocol runs 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg over 16+ weeks to minimize GI side effects
• Common research vial: 3 mg reconstituted in 1.5 mL, yielding 2 mg/mL concentration
• Use the Reconstitution Calculator to prepare your Semaglutide vial →

⚠️ Disclaimer: This article is intended for educational and research purposes only. Semaglutide (as a research compound) is not FDA-approved for human self-administration outside of licensed clinical or medical settings. Ozempic and Wegovy are FDA-approved semaglutide products available by prescription. All information presented here is drawn from published clinical research. Nothing in this article constitutes medical advice. Consult a licensed healthcare professional before use.

Semaglutide is a GLP-1 receptor agonist administered once weekly via subcutaneous injection. Typical research doses range from 0.25 mg/week (initiation) to 2.4 mg/week (full research dose). The most common research vial is 3 mg reconstituted in 1.5 mL BAC water, giving a concentration of 2 mg/mL.

All unit values assume a standard U-100 insulin syringe (100 units = 1 mL).

Calculate semaglutide syringe units →

Standard Research Escalation Protocol: 0.25 mg to 2.4 mg/Week

Attempting to begin semaglutide research at the full dose is strongly associated with severe nausea, vomiting, and early discontinuation. The standard escalation mirrors the FDA-approved Wegovy titration schedule — a gradual stepwise increase over 16+ weeks to allow GI tolerance to develop.

Some research protocols use a simplified 4-step escalation that skips the 1.7 mg step, moving from 1.0 mg directly to 2.0 mg at week 13. The more conservative 5-step protocol is generally preferred for subjects with a history of significant GI sensitivity. Escalation can be paused at any step — extending a lower dose phase by 4 additional weeks before advancing is a well-supported strategy.

What Is Semaglutide?

Semaglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk. It was engineered from native GLP-1 with two key structural modifications: substitution of alanine at position 8 with 2-aminoisobutyric acid (to resist DPP-4 degradation) and attachment of a C18 fatty diacid chain via a linker at lysine-26 (to enable albumin binding and extend half-life). These modifications extend the half-life from native GLP-1's roughly 2 minutes to approximately 165–184 hours — enabling once-weekly subcutaneous dosing.

Native GLP-1 is an incretin hormone secreted by L-cells in the small intestine in response to nutrient ingestion. Its physiological roles include stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and signaling satiety to the hypothalamus. Semaglutide activates the same GLP-1 receptor with 94% sequence homology to the native hormone, exerting all of these effects at a sustained level that persists throughout the week rather than only during and after meals.

The compound is available in research vial form (lyophilized powder) as well as in the commercial auto-injector pen format in clinical settings. For research purposes, the lyophilized vial format is typically used, reconstituted with bacteriostatic water and drawn with standard insulin syringes. Semaglutide has a molecular weight of approximately 4,113.6 Da.

Mechanism of Action

Semaglutide's weight-reduction effects are mediated through multiple simultaneous pathways at the GLP-1 receptor, which is expressed in the pancreas, gut, brain, heart, and kidneys.

Satiety and appetite suppression is the primary mechanism for weight loss. GLP-1 receptors in the hypothalamus and brainstem (specifically the nucleus tractus solitarius and the arcuate nucleus) are directly activated by semaglutide, reducing appetite-stimulating neuropeptide Y (NPY) and AgRP signaling while increasing POMC and CART expression — neuropeptides that promote satiety. This central mechanism produces a pronounced reduction in food cravings and caloric intake consistently observed across clinical research.

Gastric emptying deceleration further reinforces the satiety effect. By slowing the rate at which food moves from the stomach to the small intestine, semaglutide prolongs the sense of fullness after a meal and reduces postprandial glucose excursions. This effect is more pronounced in the early weeks of treatment and tends to moderate somewhat over time — a pattern that may explain why GI side effects are most prominent during dose escalation.

Glucose-dependent insulin secretion is the mechanism underlying semaglutide's original indication in type 2 diabetes. GLP-1 receptor activation in pancreatic beta cells augments glucose-stimulated insulin release, improving postprandial glucose clearance. Critically, this effect is glucose-dependent — the compound does not stimulate insulin secretion in the absence of elevated blood glucose, which significantly limits hypoglycemia risk compared to sulfonylureas or exogenous insulin.

Glucagon suppression in pancreatic alpha cells also contributes to improved glucose control by reducing hepatic glucose output. Taken together, these mechanisms make semaglutide an unusually comprehensive metabolic regulator — acting simultaneously on appetite, gastric motility, insulin dynamics, and glucagon.

STEP Trial Data

The STEP (Semaglutide Treatment Effect in People with Obesity) trial series, published primarily in the New England Journal of Medicine between 2021 and 2022, represents the most rigorous clinical evidence base for semaglutide's weight management efficacy.

STEP 1 (n=1,961): Non-diabetic adults with obesity received 2.4 mg semaglutide/week versus placebo for 68 weeks. Mean weight reduction in the semaglutide group was 14.9% of baseline body weight (approximately 15.3 kg absolute), compared to 2.4% in the placebo group. 86.4% of semaglutide participants achieved ≥5% weight loss; 69.1% achieved ≥10%; 50.5% achieved ≥15%.

STEP 2 (n=1,210): Adults with type 2 diabetes, 2.4 mg semaglutide for 68 weeks. Mean weight reduction was 9.6% — lower than STEP 1, consistent with the known metabolic resistance to weight loss in insulin-resistant populations.

STEP 3 (n=611): 2.4 mg semaglutide plus intensive behavioral therapy. Mean weight loss reached 16.0%, suggesting that behavioral intervention compounds the pharmacological effect.

STEP 5 (n=304): 104-week extension. At 2 years, 2.4 mg semaglutide maintained mean weight loss of 15.2% — demonstrating durability of effect during continued treatment.

The most commonly reported adverse events were gastrointestinal — nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) — predominantly during the dose escalation phase. Serious adverse events were more frequent in the semaglutide group (9.8%) versus placebo (6.4%), though this difference was largely attributable to GI events rather than cardiovascular or other serious harm.

Semaglutide vs. Tirzepatide vs. Retatrutide

The GLP-1 agonist space has evolved rapidly. Semaglutide, a selective GLP-1 receptor agonist, now has competition from dual and triple agonists that target multiple incretin receptors simultaneously.

Tirzepatide's co-activation of the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) appears to augment the GLP-1 effect through complementary pathways — GIP receptor activation promotes lipid storage regulation in adipose tissue and potentially augments GLP-1-driven satiety signaling. The SURMOUNT-1 trial showed ~20.9% weight reduction at 15 mg, significantly surpassing semaglutide's STEP-1 results.

Retatrutide's additional glucagon receptor (GcgR) agonism adds a third mechanism: direct stimulation of energy expenditure through glucagon-driven thermogenesis and increased hepatic fat oxidation. Phase 2 data suggested mean weight loss of ~24.2% at 48 weeks, though the longer-term profile is still being characterized in Phase 3.

See the Tirzepatide research guide → | See the Retatrutide research guide →

Using the Calculator

Given the escalation-based nature of semaglutide research protocols, the reconstitution calculator is especially valuable for tracking the changing dose volumes across phases. Rather than recalculating manually each week, you can set your reconstitution concentration once and refer to the output table for each escalation step.

When entering parameters, use your actual reconstitution volume (not the vial size) as the solvent volume. For a 3 mg vial reconstituted in 1.5 mL, enter: mg=3, ml=1.5, and your target dose in micrograms (e.g., dose=250 for the 0.25 mg initiation phase). The calculator will output the exact syringe volume and unit count for your specific setup.

Open the Reconstitution Calculator →

Frequently Asked Questions About Semaglutide

Q: What is the semaglutide dose escalation protocol? A: The standard escalation follows a stepwise increase over 16+ weeks: 0.25 mg/week for weeks 1–4, 0.5 mg for weeks 5–8, 1.0 mg for weeks 9–12, 1.7 mg for weeks 13–16, then 2.0 mg/week as the maintenance dose. This gradual titration is designed to allow gastrointestinal tolerance to develop — the nausea, early satiety, and vomiting that occur with semaglutide are most pronounced during dose escalation and are significantly worse if the full dose is started immediately.

Q: How do you reconstitute semaglutide from a research vial? A: The most common reconstitution is a 3 mg vial dissolved in 1.5 mL of bacteriostatic water, yielding a 2 mg/mL concentration. At this concentration, the 0.25 mg initiation dose requires 0.125 mL (12.5 units on a U-100 insulin syringe), and the 2.0 mg maintenance dose requires exactly 1.0 mL (100 units) — the maximum practical volume for a single subcutaneous injection. Always inject the BAC water slowly down the vial wall, swirl gently, and never shake.

Q: What is the difference between semaglutide and Ozempic? A: Ozempic is the FDA-approved brand-name product containing semaglutide at 0.5 mg, 1 mg, and 2 mg doses, delivered via a pre-filled auto-injector pen, approved for type 2 diabetes management. Wegovy is the FDA-approved semaglutide product at 2.4 mg/week specifically approved for chronic weight management. Research-grade semaglutide refers to the same active compound supplied as lyophilized powder in vials for reconstitution, intended for research purposes and not for clinical therapeutic use outside of licensed settings.

Q: How much weight loss does semaglutide cause in clinical research? A: The STEP-1 trial found a mean body weight reduction of 14.9% (approximately 15.3 kg) over 68 weeks at 2.4 mg/week in non-diabetic adults with obesity, compared to 2.4% in the placebo group. 86.4% of semaglutide participants achieved at least 5% weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15%. Results are somewhat lower in people with type 2 diabetes (STEP-2: ~9.6% weight reduction).

Q: How does semaglutide compare to tirzepatide for weight loss? A: Tirzepatide, a dual GLP-1/GIP receptor agonist, produces greater weight loss than semaglutide in available trial data — the SURMOUNT-1 trial showed ~20.9% mean weight reduction at 15 mg tirzepatide over 72 weeks, compared to semaglutide's ~14.9% in STEP-1. The additional GIP receptor co-agonism in tirzepatide appears to augment the GLP-1-driven satiety and metabolic effects. Semaglutide remains the more extensively characterized compound with the longest follow-up data, while tirzepatide is now FDA-approved as Mounjaro and Zepbound.

Ready to calculate your semaglutide dose?

→ Open Semaglutide in the Reconstitution Calculator

→ View the Full GLP-1 Peptides Comparison

This content is intended for research and educational purposes only. Semaglutide as a research compound is not approved for self-administration outside of licensed medical or clinical settings. All research use should comply with applicable regulations and institutional guidelines.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions